| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Chatzidionysiou, K., et al.
(författare)
-
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
- 2021
-
Ingår i: Journal of Rheumatology. - : The Journal of Rheumatology. - 0315-162X .- 1499-2752. ; 48:10, s. 1512-1518
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. In rheumatoid arthritis (RA), evidence regarding the effectiveness of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients whose first-ever bDMARD was a non-tumor necrosis factor inhibitor (TNFi) bDMARD is limited. The objective of this study was therefore to assess the outcome of a second bDMARD (non-TNFi: rituximab [RTX], abatacept [ABA], or tocilizumab [TCZ], separately; and TNFi) after failure of a non-TNFi bDMARD as first bDMARD. Methods. We identified patients with RA from the 5 Nordic biologics registers who started treatment with a non-TNFi as first-ever bDMARD but switched to a second bDMARD. For the second bDMARD, we assessed drug survival (at 6 and 12 months) and primary response (at 6 months). Results. We included 620 patients starting a second bDMARD (ABA 86, RTX 40, TCZ 67, and TNFi 427) following failure of a first non-TNFi bDMARD. At 6 and 12 months after start of their second bDMARD, approximately 70% and 60%, respectively, remained on treatment, and at 6 months, less than one-third of patients were still on their second bDMARD and had reached low disease activity or remission according to the Disease Activity Score in 28 joints. For those patients whose second bMDARD was a TNFi, the corresponding proportion was slightly higher (40%). Conclusion. The drug survival and primary response of a second bDMARD in patients with RA switching due to failure of a non-TNFi bDMARD as first bDMARD is modest. Some patients may benefit from TNFi when used after failure of a non-TNFi as first bDMARD.
|
|
| 5. |
- Melin, M. C., et al.
(författare)
-
Where do people direct their attention while cycling? A comparison of adults and children
- 2018
-
Ingår i: Transportation Research Part F: Traffic Psychology and Behaviour. - : Elsevier BV. - 1369-8478. ; 58, s. 292-301
-
Tidskriftsartikel (refereegranskat)abstract
- Cycling in urban environments requires the ability to distinguish between relevant and irrelevant targets quickly and reliably, so that potential hazards can be anticipated and avoided. In two experiments, we investigated where adults and children direct their attention when viewing videos filmed from a cyclist's perspective. We wanted to see if there were any differences in the responses given by experienced adult cyclists, inexperienced adult cyclists, and child cyclists. In Experiment 1, 16 adults (19–33 years) were asked to watch ten videos and to point out things they would pay attention to by tapping a touchscreen (pointed out locations). Afterwards, they were asked to explain their answers. In Experiment 2, 17 adults (19–34 years) and 17 children (11–12 years) performed the same task with the same ten videos, but they were not asked to explain their answers afterwards. The data sets from these two experiments were pooled, creating three groups: ten experienced adult cyclists, 23 inexperienced adult cyclists and 17 children. A total of 23 clearly visible, traffic-relevant targets (pre-specified targets) had previously been identified in the videos. We investigated whether the participants’ pointed-out locations matched these targets (and if so, how fast they responded in pointing them out). We also investigated the number and vertical/horizontal dispersion of these pointed-out locations on the touchscreen. Adults pointed out more locations than children, especially pedestrians and cyclists. This result suggests that, while children focussed as well as adults on cars (arguably the most salient hazard), they were less able to identify other hazards (such as pedestrians or other cyclists). The children had also a larger vertical dispersion and a larger between-participant variation than the adults. Adults were faster at tapping the pre-specified targets and they missed them less often. Overall, the results suggest that 11–12 year old-cyclists have worse situation awareness in traffic than adults.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Nissinen, R, et al.
(författare)
-
Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis
- 2004
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 63:6, s. 681-687
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: To analyse immunological changes during treatment with a monoclonal anti-tumour necrosis factor α (TNFα) antibody, infliximab, in patients with rheumatoid arthritis (RA). Methods: 25 patients with RA and 5 patients with other arthritides were studied during the first 6 weeks of treatment with infliximab. At the start of treatment and after 2 and 6 weeks, spontaneous expression of CCR3 and CCR5 on peripheral blood T cells and monocytes was studied by flow cytometry. The secretion and mRNA expression of interferon γ (IFNγ), interleukin (IL)4, IL5, and TNFα from phytohaemagglutinin (PHA) stimulated peripheral blood mononuclear cells was measured with an ELISA and RT-PCR. Plasma levels of C reactive protein, serum amyloid protein A, rheumatoid factor, and antibodies to filaggrin and citrullinated cyclic peptide were measured with an ELISA. Results: The number of CD4 T cells and CD14 monocytes expressing CCR3 (p = 0.013, p = 0.009, respectively) and CD8 T cells expressing CCR5 (p = 0.040) as well as PHA stimulated secretion of IL4 and IFNγ (p<0.05) increased during treatment in patients with RA. 15 (60%) patients with RA achieved clinical response (at least ACR20) during the first 2 weeks. The number of T cells expressing CCR3 and CCR5 was higher before treatment in non-responders than in responders (p<0.05). The number of T cells increased in responders. Conclusion: Increase in secretion of Th1 and Th2 cytokines together with induced expression of chemokine receptors on T cells and monocytes suggest restoration of peripheral cell mediated immunity and blockade of the accumulation of inflammatory cells in joints as response to treatment.
|
|
| 9. |
|
|
